These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. Strassner JP; Rashighi M; Ahmed Refat M; Richmond JM; Harris JE J Am Acad Dermatol; 2017 May; 76(5):847-855.e5. PubMed ID: 28259440 [TBL] [Abstract][Full Text] [Related]
6. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy. Shao K; McGettigan S; Elenitsas R; Chu EY J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121 [TBL] [Abstract][Full Text] [Related]
7. A similar local immune and oxidative stress phenotype in vitiligo and halo nevus. Yang Y; Li S; Zhu G; Zhang Q; Wang G; Gao T; Li C; Wang L; Jian Z J Dermatol Sci; 2017 Jul; 87(1):50-59. PubMed ID: 28385330 [TBL] [Abstract][Full Text] [Related]
8. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Rashighi M; Agarwal P; Richmond JM; Harris TH; Dresser K; Su MW; Zhou Y; Deng A; Hunter CA; Luster AD; Harris JE Sci Transl Med; 2014 Feb; 6(223):223ra23. PubMed ID: 24523323 [TBL] [Abstract][Full Text] [Related]
9. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. Jour G; Glitza IC; Ellis RM; Torres-Cabala CA; Tetzlaff MT; Li JY; Nagarajan P; Huen A; Aung PP; Ivan D; Drucker CR; Prieto VG; Rapini RP; Patel A; Curry JL J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658 [TBL] [Abstract][Full Text] [Related]
10. Role of chemokines and the corresponding receptors in vitiligo: A pilot study. Yang L; Yang S; Lei J; Hu W; Chen R; Lin F; Xu AE J Dermatol; 2018 Jan; 45(1):31-38. PubMed ID: 29115683 [TBL] [Abstract][Full Text] [Related]
11. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Wang XX; Wang QQ; Wu JQ; Jiang M; Chen L; Zhang CF; Xiang LH Br J Dermatol; 2016 Jun; 174(6):1318-26. PubMed ID: 26801009 [TBL] [Abstract][Full Text] [Related]
12. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829 [TBL] [Abstract][Full Text] [Related]
13. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients. Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192 [No Abstract] [Full Text] [Related]
17. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. Kao JC; Liao B; Markovic SN; Klein CJ; Naddaf E; Staff NP; Liewluck T; Hammack JE; Sandroni P; Finnes H; Mauermann ML JAMA Neurol; 2017 Oct; 74(10):1216-1222. PubMed ID: 28873125 [TBL] [Abstract][Full Text] [Related]
18. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma. Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066 [TBL] [Abstract][Full Text] [Related]
19. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054 [TBL] [Abstract][Full Text] [Related]
20. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab. Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]